Misplaced Pages

Rosmantuzumab (INN; development code OMP-131R10) is a humanized monoclonal antibody designed for the treatment of cancer.

This drug was developed by OncoMed Pharmaceuticals.

References

1. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
2. Katoh M (August 2018). "Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review)". Int. J. Mol. Med. 42 (2): 713–725. doi:10.3892/ijmm.2018.3689. PMC 6034925. PMID 29786110.
3. Katoh M (November 2017). "Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)". Int. J. Oncol. 51 (5): 1357–1369. doi:10.3892/ijo.2017.4129. PMC 5642388. PMID 29048660.
4. Katoh M, Katoh M (September 2017). "Molecular genetics and targeted therapy of WNT-related human diseases (Review)". Int. J. Mol. Med. 40 (3): 587–606. doi:10.3892/ijmm.2017.3071. PMC 5547940. PMID 28731148.
5. Statement On A Nonproprietary Name Adopted By The USAN Council - Rosmantuzumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibody stubs
• Monoclonal antibodies